Thomson Pharma Now Provides Early Warning Of Generic Drug Development
Philadelphia, PA - Thomson Scientific, a business of The Thomson Corporation, announced an important new enhancement to Thomson Pharma(SM) -- the drug discovery and development information solution that fulfills the information needs of professionals working at all stages of the drug development pipeline.
The new Thomson Pharma Generic Competition Module, which will be launched June 2006, is a strategic tool for research-based innovator, specialty and niche- brand pharmaceutical companies. The module provides critical, early intelligence and independent analysis to help companies identify and assess the earliest signs of generic competition for brand products, in addition to the ability to continuously track and monitor ongoing developments.
The Thomson Pharma Generic Competition Module is derived from the Vision CITM system (originally developed by Newport Strategies, Inc., which was acquired by Thomson in April 2004). Within Thomson Pharma, the Generic Competition Module provides Product Lifecycle Management teams with the analysis by which to forecast loss of product exclusivity, the ability to quickly identify competition, and the potential effects of generic entry on their competitor's products.
For those in Competitive Intelligence, the module gives pharmaceutical companies an invaluable tool for identifying and tracking early generics activity, and researching potential competitors.
Attorneys and Intellectual Property Professionals will find the module particularly useful for spotting potential patent challenges, recognizing alternative forms and for indications of other patent circumvention strategies.
"The Thomson Pharma Generic Competition Module answers the concerns of innovator companies by providing the critical information they need to determine and assess the likely source, impact, and timing of potential generic competition; to predict the level of generic interest in and competitiveness for products based on unique early intelligence surrounding the development of the generic active pharmaceutical ingredient (API)," said Jon Brett-Harris, executive vice president of Pharmaceutical and Chemical markets at Thomson Scientific. "The module is a welcome addition to Thomson Pharma, as it will give our users the tools to assess likely relationships between API suppliers and generic companies, while improving planning and management of product life cycles," added Brett-Harris.
SOURCE: Thomson Corporation